Actinium Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $90,000 | — | $81,000 | $1.0M | $1.1M |
| Operating income | -$36.2M | -$42.1M | -$51.9M | -$34.1M | -$25.0M |
| Operating expenses | $36.3M | $42.1M | $52.0M | $35.1M | $26.1M |
| Cost of revenue | — | — | — | — | $900,000 |
| Cash from operations | -$24.6M | -$33.1M | -$47.3M | $8.6M | -$20.9M |
| Capital expenditure | $104,000 | $11,000 | $153,000 | $366,000 | $133,000 |
| Free cash flow | -$24.7M | -$33.1M | -$47.5M | $8.3M | -$21.0M |
| Total assets | $51.8M | $76.9M | $81.4M | $114.2M | $80.4M |
| Total liabilities | $43.9M | $44.1M | $45.1M | $47.7M | $6.8M |
Shares outstanding 31.4M · Free float 99.4%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.